ArriVent BioPharma, Inc. 10-K

Item 8. Financial Statements and Supplementary Data ​ ​ 139 Table of Contents ARRIVENT BIOPHARMA, INC. INDEX TO FINANCIAL STATEMENTS ​ Page Report of Independent Registered Public Accounting Firm (KPMG LLP, Philadelphia, PA, Audit Firm ID: 185) F-2 ​ ​ ​ Balance Sheets as of December 31, 2023 and 2022 ​ F-3 ​ ​ ​ Statements of Operations for the Years Ended December 31, 2023 and 2022 ​ F-4 ​ ​ ​ Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the Years Ended December 31, 2023 and 2022 ​ F-5 ​ ​ ​ Statements of Cash Flows for the Years Ended December 31, 2023 and 2022 ​ F-6 ​ ​ ​ Notes to Financial Statements ​ F-7 ​ ​ ​ ​ ​ ​ ​ ​ F-1 Table of Contents Report of Independent Registered Public Accounting Firm To the Stockholders and Board of Directors ArriVent BioPharma, Inc.: Opinion on the Financial Statements We have audited the accompanying balance sheets of ArriVent BioPharma, Inc. (the Company) as of December 31, 2023 and 2022, the related statements of operations, convertible preferred stock and stockholders’ equity (deficit), and cash flows for the years then ended and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles. Basis for Opinion These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. /s/ KPMG LLP We have served as the Company’s auditor since 2023 Philadelphia, Pennsylvania March 28, 2024 ​ ​ ​ . ​ F-2 Table of Contents ARRIVENT BIOPHARMA, INC. BALANCE SHEETS (in thousands, except share and per share data) ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2023 2022 Assets ​ ​ Current assets: ​ ​ Cash and cash equivalents ​ $ 150,389 ​ $ 163,372 Prepaid expenses and other current assets ​ 9,579 ​ 19,250 Total current assets ​ 159,968 ​ 182,622 Right of use assets – operating leases ​ 291 ​ 139 Deferred offering costs ​ ​ 2,732 ​ ​ — Other assets ​ 107 ​ 72 Total assets ​ $ 163,098 ​ $ 182,833 ​ ​ ​ ​ ​ ​ ​ Liabilities, Convertible Preferred Stock and Stockholders’ (Deficit) ​ ​ Current liabilities: ​ ​ Accounts payable ​ $ 4,532 ​ $ 3,094 Accrued expenses ​ 6,952 ​ 5,138 Operating lease liabilities ​ 140 ​ 128 Total current liabilities ​ 11,624 ​ 8,360 Operating lease liabilities ​ 177 ​ 11 Total liabilities ​ 11,801 ​ 8,371 ​ ​ ​ ​ ​ ​ ​ Commitments and contingencies (Note 7) ​ ​ ​ ​ ​ ​ ​ ​ ​ Series A convertible preferred stock $0.0001 par value, 150,000,000 shares authorized; 150,000,000 shares issued and outstanding at December 31, 2023 and 2022; liquidation preference of $150,000 at December 31, 2023 ​ 149,865 ​ 149,865 Series B convertible preferred stock $0.0001 par value, 147,619,034 shares authorized; 147,619,034 and 104,761,894 shares issued and outstanding at December 31, 2023 and 2022, respectively; liquidation preference of $155,000 at December 31, 2023 ​ ​ 154,625 ​ ​ 109,706 ​ ​ ​ ​ ​ ​ ​ Stockholders’ (deficit): ​ ​ ​ ​ ​ ​ Common stock $0.0001 par value, 368,600,500 shares authorized; 2,745,480 and 2,597,738 shares issued and outstanding at December 31, 2023 and 2022, respectively ​ ​ — ​ ​ — Additional paid-in capital ​ 4,652 ​ 3,403 Accumulated deficit ​ (157,845) ​ (88,512) Total stockholders’ (deficit) ​ (153,193) ​ (85,109) Total liabilities, convertible preferred stock and stockholders’ (deficit) ​ $ 163,098 ​ $ 182,833 ​ See accompanying notes to financial statements. ​ ​ F-3 Table of Contents ARRIVENT BIOPHARMA, INC. STATEMENTS OF OPERATIONS (in thousands, except share and per share data) ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2023 2022 Operating expenses: ​ ​ Research and development $ 64,884 $ 30,433 General and administrative ​ 9,706 ​ 6,473 Total operating expenses ​ 74,590 ​ 36,906 Operating loss ​ (74,590) ​ (36,906) Interest income ​ ​ 5,257 ​ ​ — Net loss ​ $ (69,333) ​ $ (36,906) ​ ​ ​ ​ ​ ​ ​ Share information: ​ ​ Net loss per share of common stock, basic and diluted ​ $ (32.38) ​ $ (28.90) Weighted-average shares of common stock outstanding, basic and diluted ​ 2,140,951 ​ 1,277,079 ​ See accompanying notes to financial statements. ​ ​ F-4 Table of Contents ARRIVENT BIOPHARMA, INC. STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT) (in thousands, except share and per share data) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Series A ​ Series B ​ ​ Series A ​ ​ ​ ​ ​ ​ ​ ​ ​ Additional ​ ​ ​ ​ ​ ​ ​ convertible preferred stock ​ convertible preferred stock ​ ​ convertible preferred stock ​ Common stock ​ Subscription ​ paid-in ​ Accumulated ​ ​ ​ Shares Amount Shares Amount Shares Amount Shares Amount receivable capital deficit Total Balance, January 1, 2022 — ​ $ — — ​ $ — ​ 90,000,000 ​ $ 89,865 ​ 2,591,164 ​ $ — ​ $ (2) ​ $ 2,964 ​ $ (51,606) ​ $ 41,221 Issuance of Series A convertible preferred stock at $1.00 per share 60,000,000 ​ 60,000 — ​ — ​ — ​ — ​ — ​ — ​ ​ — ​ — ​ — ​ — Issuance of Series B convertible preferred stock at $1.05 per share, net of issuance costs of $294 — ​ — 104,761,894 ​ 109,706 ​ — ​ — ​ — ​ — ​ ​ — ​ — ​ — ​ — Reclassification of Series A convertible preferred stock ​ 90,000,000 ​ ​ 89,865 ​ — ​ ​ — ​ ​ (90,000,000) ​ ​ (89,865) ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ (89,865) Payment of subscription receivable ​ — ​ — — ​ — ​ ​ — ​ — ​ 6,574 ​ — ​ ​ 2 ​ ​ — ​ ​ — ​ ​ 2 Exercise of stock options — ​ — — ​ — ​ — ​ — ​ — ​ — ​ ​ — ​ 15 ​ — ​ 15 Stock-based compensation expense — ​ — — ​ — ​ — ​ — ​ — ​ — ​ ​ — ​ 424 ​ — ​ 424 Net loss — ​ — — ​ — ​ — ​ — ​ — ​ — ​ ​ — ​ — ​ (36,906) ​ (36,906) Balance, December 31, 2022 150,000,000 ​ ​ 149,865 104,761,894 ​ ​ 109,706 ​ — ​ ​ — ​ 2,597,738 ​ ​ — ​ ​ — ​ ​ 3,403 ​ ​ (88,512) ​ ​ (85,109) Issuance of Series B convertible preferred stock at $1.05 per share, net of issuance costs of $81 — ​ — 42,857,140 ​ 44,919 ​ — ​ — ​ — ​ — ​ ​ — ​ — ​ — ​ — Repurchase of common stock ​ — ​ — — ​ — ​ ​ — ​ — ​ (7,387) ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — Exercise of stock options — ​ — — ​ — ​ — ​ — ​ 155,129 ​ — ​ ​ — ​ 354 ​ — ​ 354 Stock-based compensation expense — ​ — — ​ — ​ — ​ — ​ — ​ — ​ ​ — ​ 895 ​ — ​ 895 Net loss — ​ — — ​ — ​ — ​ — ​ — ​ — ​ ​ — ​ — ​ (69,333) ​ (69,333) Balance, December 31, 2023 150,000,000 ​ $ 149,865 147,619,034 ​ $ 154,625 ​ — ​ $ — ​ 2,745,480 ​ $ — ​ $ — ​ $ 4,652 ​ $ (157,845) ​ $ (153,193) ​ ​ ​ See accompanying notes to financial statements. ​ ​ ​ F-5 Table of Contents ARRIVENT BIOPHARMA, INC. STATEMENTS OF CASH FLOWS (in thousands) ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2023 2022 Cash flows from operating activities: ​ ​ Net loss ​ $ (69,333) ​ $ (36,906) Adjustment to reconcile net loss to net cash used in operating activities: ​ ​ Stock-based compensation expense ​ 895 ​ 424 Changes in operating assets and liabilities: ​ ​ Prepaid expenses and other current assets ​ 9,671 ​ (13,578) Other assets ​ (35) ​ 16 Accounts payable ​ ​ 1,379 ​ ​ 2,800 Accrued expenses ​ 1,556 ​ 3,613 Operating lease liabilities ​ 25 ​ — Net cash used in operating activities ​ (55,842) ​ (43,631) Cash flows from investing activities: ​ ​ Purchase of short-term investments ​ (25,000) ​ — Maturity of short-term investments ​ 25,000 ​ — Net cash used in investing activities ​ — ​ — Cash flows from financing activities: ​ ​ Proceeds from issuance of common stock ​ — ​ 2 Proceeds from the exercise of stock options ​ 354 ​ 15 Proceeds from the sale of Series A convertible preferred stock, net of issuance costs ​ — ​ 60,000 Proceeds from the sale of Series B convertible preferred stock, net of issuance costs ​ 44,919 ​ 109,706 Payment of deferred offering costs ​ (2,414) ​ — Net cash provided by financing activities ​ 42,859 ​ 169,723 ​ ​ ​ ​ ​ ​ ​ Net (decrease) increase in cash and cash equivalents ​ (12,983) ​ 126,092 Cash and cash equivalents at beginning of the year ​ 163,372 ​ 37,280 Cash and cash equivalents at end of the year ​ $ 150,389 ​ $ 163,372 ​ ​ ​ ​ ​ ​ ​ Supplemental disclosures of non-cash financing and investing activities ​ ​ Deferred offering costs included in accounts payable ​ $ 318 ​ $ — Right-of-use assets obtained in exchange for new operating lease liabilities ​ ​ 300 ​ ​ 260 ​ See accompanying notes to financial statements. ​ ​ F-6 Table of Contents ARRIVENT BIOPHARMA, INC. NOTES TO THE FINANCIAL STATEMENTS (1) Background ArriVent BioPharma, Inc., a Delaware Corporation (the “Company”), founded on April 14, 2021, is a clinical-stage biopharmaceutical company focused on identifying, licensing and globalizing top biopharma innovations from around the world to deliver important medicines to patients. In June 2021, the Company entered into a license agreement with Shanghai Allist Pharmaceuticals Co. Ltd. (“Allist”) which granted the Company an exclusive license under certain intellectual property owned or controlled by Allist to develop, manufacture and commercialize any product containing furmonertinib or any of its derivatives as an active ingredient, for all uses, in all countries and territories other than greater China, which includes mainland China, Hong Kong, Macau and Taiwan (See Note 11). The Company’s lead development candidate, furmonertinib, is a third-generation tyrosine kinase inhibitor currently being evaluated in multiple clinical trials across a range of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC), many for which there are limited treatment options. ​ On January 30, 2024, the Company completed the closing of its initial public offering of 9,722,222 shares of common stock at a price of $18.00 per share. Additionally, the underwriters exercised their option to purchase an additional 1,458,333 shares of common stock at a price of $18.00 per share. The shares of common stock began trading on the Nasdaq Global Market on January 26, 2024, under the symbol “AVBP”. The Company received net proceeds of $183.4 million, after deducting underwriting discounts and commissions and other estimated offering expenses. In addition, as a result of the closing of the Company’s initial public offering, the Company’s Series A and Series B convertible preferred stock converted into 19,567,306 shares of common stock in January 2024. ​ ​ (2) Development-Stage Risks and Liquidity The Company has incurred losses since inception and has an accumulated deficit of $157.8 million as of December 31, 2023. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales from its product candidates currently in development. Management believes that cash and cash equivalents of $150.4 million as of December 31, 2023, together with the net proceeds from the initial public offering, are sufficient to sustain planned operations through at least twelve months from the issuance date of these financial statements. The Company is subject to those risks associated with any specialty biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. ​ (3) Summary of Significant Accounting Policies (a) Basis of Presentation The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). Any references in these notes to applicable guidance are meant to refer to GAAP as found in Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) promulgated by the Financial Accounting Standards Board (“FASB”). (b) Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at F-7 Table of Contents ARRIVENT BIOPHARMA, INC. NOTES TO THE FINANCIAL STATEMENTS the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from such estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the financial statements in the period they are determined to be necessary. Significant areas that require management’s estimates include the fair value of the Company’s common stock, stock-based compensation expense assumptions and accrued research and development expenses. (c) Fair Value Measurements The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels: • Level 1 Inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. • Level 2 Inputs: Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. • Level 3 Inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. ​Management believes that the carrying amounts of the Company’s financial instruments, principally cash equivalents and accounts payable, approximate fair value due to the short-term nature of those instruments. (d) Concentration of credit risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains cash in a checking account with a federally insured financial institution in excess of federally insured limits. Cash equivalents are defined as all liquid investments with maturity from date of purchase of 90 days or less that are readily convertible into cash and consist of money market funds and certificates of deposit. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash. (e) Leases Effective January 1, 2022, the Company adopted ASU No. 2016-02, Leases (Topic 842) , as amended. Under the guidance, the Company determines whether an arrangement is or contains a lease, its classification, and its term at the lease commencement date. Leases with a term greater than one year will be recognized on the balance sheet as right-of-use (“ROU”) assets, current lease liabilities, and if applicable, long-term lease liabilities. The Company has elected certain practical expedients permitted under the transition guidance to not record short-term leases (terms less than 12 months during 2022). Lease liabilities and the corresponding ROU assets are recorded based on the present values of lease payments over the lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rates, which are the rates that would be incurred to borrow on a collateralized basis, over similar terms, amounts equal to the lease payments in a similar economic environment. Payments for non-lease components or that are variable in nature that do not depend on a rate or index are not included in the lease liability and are typically expensed as incurred. If significant events, changes in circumstances, F-8 Table of Contents ARRIVENT BIOPHARMA, INC. NOTES TO THE FINANCIAL STATEMENTS or other events indicate that the lease term or other inputs have changed, the Company would reassess lease classification, remeasure the lease liability using revised inputs as of the reassessment date, and adjust the ROU assets. Lease expense is recognized on a straight-line basis over the expected lease term for operating-classified leases. (f) Research and Development Costs Research and development costs are recorded as expense as incurred and principally consist of personnel costs as well as amounts paid to third parties for up-front and milestone payments made for services provided and related supply costs. (g) Stock-Based Compensation Expense The Company measures stock-based awards, including stock options, at their grant-date fair value and records compensation expense over the requisite service period, which is the vesting period of the awards. The Company accounts for forfeitures as they occur. Estimating the fair value of stock options requires the use of subjective assumptions, including the fair value of the Company’s common stock, the expected term of the option and expected stock price volatility. The Company uses the Black-Scholes option-pricing model to value its stock option awards. The assumptions used in calculating the fair value of stock options represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards. The fair value of the Company’s common stock is estimated by the Company’s board of directors, with input from management considering the most recently available third-party valuation of the Company’s common stock. The expected term of stock options for employees is estimated using the “simplified method,” as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting date and the contractual term of the option. The contractual term is used as the expected term for stock options granted to non-employees. For stock price volatility, the Company uses comparable public companies as a basis for the expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected term of the option. The expected dividend yield is zero given the Company does not expect to pay dividends for the foreseeable future. (h) Net Loss per Share Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as convertible preferred stock and stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share since when a net loss exists, potentially dilutive securities are not included in the calculation as their impact is anti-dilutive. The Company’s convertible preferred stock entitles the holder to participate in dividends and earnings of the Company, and, if the Company were to recognize net income, it would have to use the two-class method to calculate earnings per share. The two-class method is not applicable during periods with a net loss, as the holders of the convertible preferred stock have no obligation to fund losses. F-9 Table of Contents ARRIVENT BIOPHARMA, INC. NOTES TO THE FINANCIAL STATEMENTS The following table sets forth the computation of net loss, basic and diluted (in thousands, except share and per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ Year ended December 31, ​ 2023 2022 Numerator: ​ ​ Net loss $ (69,333) $ (36,906) Denominator: ​ ​ ​ ​ ​ ​ Weighted-average shares of common stock outstanding ​ 2,633,907 ​ 2,591,993 Less: Weighted-average shares of common stock subject to repurchase ​ (492,956) ​ (1,314,914) Weighted-average shares of common stock outstanding, basic and diluted ​ 2,140,951 ​ 1,277,079 ​ ​ ​ ​ ​ ​ ​ Net loss per share attributable to common stockholders, basic and diluted ​ $ (32.38) ​ $ (28.90) ​ The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive: ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2023 2022 Series A convertible preferred stock (as converted to common stock) 9,861,923 9,861,923 Series B convertible preferred stock (as converted to common stock) 9,705,383 6,887,690 Common stock subject to repurchase ​ — ​ 1,314,914 Stock options 1,683,156 1,078,795 ​ ​ 21,250,462 ​ 19,143,322 ​ (i) Income Taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not-to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company will recognize interest and penalties related to uncertain tax positions as a component of income tax expense (benefit). F-10 Table of Contents ARRIVENT BIOPHARMA, INC. NOTES TO THE FINANCIAL STATEMENTS (j) Segment and Geographic Information Operating segments are defined as components of an enterprise (business activity from which it earns revenue and incurs expenses) about which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. The chief operating decision maker reviews operating results to make decisions about allocating resources and assessing performance for the entire company. The Company views its operations and manages its business as one operating segment. All of the Company’s assets are located in the United States. (k) Accounting Pronouncements Not Yet Adopted In November 2023, the FASB issued ASU 2023-07 Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures . This standard includes the requirements that a public entity disclose, on an annual and interim basis, significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, the title and position of the chief operating decision maker, and an explanation of how the chief operating decision maker uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. It also requires that a public entity that has a single reportable segment provide all the disclosures required by the guidance and all existing segment disclosures in ASC 280, Segment Reporting . This standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. A public entity should apply the amendments in the guidance retrospectively to all prior periods presented in the financial statements. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. The Company is currently evaluating the impact that this standard may have on its financial statements. In December 2023, the FASB issued ASU 2023-09 Income Taxes (Topic 740): Improvements to Income Tax Disclosures . This standard includes the requirement that public business entities, on an annual basis, disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold (if the effect of those reconciling items is equal to or greater than 5% of the amount computed by multiplying pretax income (or loss) by the applicable statutory income tax rate). It also requires that all entities disclose, on an annual basis, the amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign taxes and the amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid (net of refunds received) is equal to or greater than 5% of total income taxes paid (net of refunds received) and requires that all entities disclose income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign and income tax expense (or benefit) from continuing operations disaggregated by federal, state, and foreign. Lastly, this standard eliminates the requirement for all entities to disclose the nature and estimate of the range of the reasonably possible change in the unrecognized tax benefits balance in the next 12 months or make a statement that an estimate of the range cannot be made. This standard is effective for the Company for the annual period beginning January 1, 2026. Early adoption is permitted. This standard should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the impact that this standard may have on its financial statements. (l) Reverse Stock Split On January 23, 2024, the Company filed an amendment to its Articles of Incorporation and effected a 15.21-for-1 reverse stock split of its issued and outstanding shares of common stock. All common stock share and per-share amounts presented in the financial statements and related notes have been retroactively adjusted to reflect the reverse stock split. ​ F-11 Table of Contents ARRIVENT BIOPHARMA, INC. NOTES TO THE FINANCIAL STATEMENTS (4) Fair Value Measurements The following table presents information about the Company’s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2023 ​ Level 1 Level 2 Level 3 Total Current assets: ​ ​ ​ ​ ​ ​ ​ ​ Cash equivalents - money market funds ​ $ 124,322 ​ $ — ​ $ — ​ $ 124,322 Total assets measured at fair value ​ $ 124,322 ​ $ — ​ $ — ​ $ 124,322 ​ Money market accounts are highly liquid investments. The pricing information on the Company’s money market account is based on quoted prices in active markets. This approach results in a classification of these securities as Level 1 of the fair value hierarchy. ​ (5) Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2023 2022 Research and development ​ $ 8,450 ​ $ 18,417 Professional fees ​ 240 ​ 177 Insurance ​ 128 ​ 156 Tax credit receivable ​ 761 ​ 500 ​ ​ $ 9,579 ​ $ 19,250 ​ ​ (6) Accrued Expenses Accrued expenses consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2023 2022 Research and development ​ $ 3,126 ​ $ 2,299 Professional fees ​ 411 ​ 141 Compensation and related expenses ​ 3,353 ​ 2,677 Other accrued expenses ​ 62 ​ 21 ​ ​ $ 6,952 ​ $ 5,138 ​ ​ (7) Commitments and Contingencies Leases The Company has two operating leases that it subleases for its office space in California, one of which commenced in January 2022 with an original lease term through January 2024 (which ended in January 2024) and one of which commenced in November 2023 with an original lease term through January 2026. The Company also leases other space with an initial lease term of less than twelve months; therefore, it does not recognize this lease as an operating lease on the balance sheet. F-12 Table of Contents ARRIVENT BIOPHARMA, INC. NOTES TO THE FINANCIAL STATEMENTS The Company’s operating lease ROU asset and the related lease liabilities are initially measured at the present value of future lease payments over the lease term. The Company is responsible for payment of certain real estate taxes, insurance and other expenses on certain of its leases. These amounts are generally considered to be variable and are not included in the measurement of the ROU assets and lease liability. The Company accounts for non-lease components, such as maintenance, separately from lease components. Operating lease expense was $0.2 million and $0.1 million for the years ended December 31, 2023 and 2022, respectively. The Company’s remaining lease term and discount rate for its operating lease as of December 31, 2023 are 2.17 years and 9.84%, respectively. Future maturities of operating lease liabilities were as follows as of December 31, 2023 (in thousands): ​ ​ ​ ​ Fiscal year ending: ​ ​ 2024 ​ $ 165 2025 ​ ​ 173 2026 ​ 14 Total future minimum payments ​ 352 Less imputed interest ​ ​ (35) Present value of lease liabilities ​ $ 317 ​ Cash paid for rent expense recorded during the years ended December 31, 2023 and 2022 was $0.1 million and $0.2 million, respectively. Aarvik Research Agreement In December 2021, the Company entered into a Research Collaboration Agreement, as amended, effective June 2023, with Aarvik Pharmaceuticals, Inc. (“Aarvik”), under which the Company is required to pay Aarvik up to $3.1 million on statements of work (“SOWs”) and an initiation fee of $0.3 million predefined in the agreement. After the completion of the SOWs, the Company has an exclusive option to license the Aarvik intellectual property, and the option to acquire certain of Aarvik’s intellectual property, after which it is the Company’s sole responsibility to research, develop, manufacture and commercialize any applicable compound and product in the field and territory. If the Company exercises that option, it would be obligated to pay up to $18.0 million per product upon the achievement of certain clinical and regulatory milestone events and up to $80.0 million per product in commercial milestones. Additionally, the Company would be obligated to pay Aarvik royalties in the mid-single digits based on net sales of licensed products. During the years ended December 31, 2023 and 2022, the Company incurred $1.2 million and $0.5 million, respectively, in research and development expenses related to the Aarvik SOWs. Purchase Commitments The Company enters into contracts in the normal course of business with contract research organizations, contract manufacturing organizations, universities, and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts generally do not contain minimum purchase commitments and are cancellable by the Company upon prior written notice although, purchase orders for clinical materials are generally non-cancellable. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including non-cancellable obligations of the Company’s service providers, up to the date of cancellation or upon completion of a manufacturing run. F-13 Table of Contents ARRIVENT BIOPHARMA, INC. NOTES TO THE FINANCIAL STATEMENTS Employee Benefit Plan The Company maintains a 401(k) plan for employees. The 401(k) plan qualifies as a deferred salary arrangement under Section 401(k) of the Internal Revenue Code. Under the 401(k) plan, participating employees may defer a portion of their pre-tax earnings. The Company contributes 100% of employee salary deferral contributions up to 4% of pay for each payroll period. The Company contributions to the 401(k) plan during the years ended December 31, 2023 and 2022, were $0.4 million and $0.3 million, respectively. Contingencies Liabilities for loss contingencies, arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment and/or remediation can be reasonably estimated. ​ (8) Convertible Preferred Stock and Common Stock Convertible Preferred Stock In June 2021, the Company sold 90,000,000 shares of Series A convertible preferred stock (“Series A”) at an original issuance price of $1.00 per share. In February 2022, the Company sold 60,000,000 shares of Series A at an original issuance price of $1.00 per share. In December 2022, the Company sold 104,761,894 shares of Series B convertible preferred stock (“Series B”) at an original issuance price of $1.05 per share. In March 2023, the Company sold 42,857,140 shares of Series B at an original issuance price of $1.05 per share. The following is a summary of the rights, preferences, and terms of the Series A and Series B (collectively, “Convertible Preferred Stock”): Dividends The holders of the Convertible Preferred Stock are entitled to receive dividends payable when, as and if declared by the board of directors of the Company, with the holders of common stock, paid out of any assets or on the common stock of the Company, on an as-converted or as exchangeable to common stock basis. No dividends on common stock were declared or paid from inception through December 31, 2023. Voting The holders of Convertible Preferred Stock are entitled to vote on any matter presented to the stockholders of the Company. Each holder of outstanding shares of Convertible Preferred Stock is entitled to the number of votes equal to the number of shares of common stock into which the shares of Convertible Preferred Stock are convertible or exchangeable. Holders of Series A are entitled to elect two directors; holders of Series B are entitled to elect two directors; and holders of common stock are entitled to elect two directors. The holders of common stock and Convertible Preferred Stock, together as a single class, are entitled to elect the balance of the total directors of the corporation and on an as converted or exchangeable basis. As of December 31, 2023, the Company had seven directors. Liquidation Preference In the event of any voluntary or involuntary liquidations, dissolution or winding up of the Company, including a Deemed Liquidation Event (as described below), the holders of Series B shall be entitled to be paid out of the consideration payable to stockholders before any payment shall be made to the holders of Series A or common stock, an amount equal to the greater of (i) Series B original issue price, plus any dividend declared but unpaid, or (ii) such F-14 Table of Contents ARRIVENT BIOPHARMA, INC. NOTES TO THE FINANCIAL STATEMENTS amount per share as would have been payable had all shares of Series B been converted into common stock immediately prior to liquidation, dissolution or winding up. The holders of Series A shall be entitled to be paid out of the consideration payable to stockholders after any payment to the holders of Series B but before any payment shall be made to the holders common stock, an amount equal to the greater of (i) Series A original issue price, plus any dividend declared but unpaid, or (ii) such amount per share as would have been payable had all shares of Series A been converted into common stock immediately prior to liquidation, dissolution or winding up. As of December 31, 2023, the liquidation amount is $1.00 per share for the Series A and $1.05 per share for the Series B. A Deemed Liquidation Event shall include a merger or consolidation in which the Company is a constituent party (other than one in which the current stockholders of the Company own a majority of the voting power of the outstanding shares of the surviving company) or the sale, lease, transfer, exclusive license or other disposition of all or substantially all of the business or assets of the Company. Classification of Convertible Preferred Stock Upon the second closing of the Series A in February 2022, the Series A and Series B have been classified outside of stockholders’ equity (deficit) because the holders of such shares have redemption rights in the event of a Deemed Liquidation Event that is not solely within the control of the Company. Because the occurrence of a Deemed Liquidation Event is not currently probable, the carrying values of the Convertible Preferred Stock are not being accreted to their redemption values. Conversion The Convertible Preferred Stock is convertible into common stock based on the original issuance price of the security, which is the Conversion Price, subject to certain anti-dilution provisions in the event of a future issuance of preferred stock which creates a down round. The Conversion Price is $15.21 per share for Series A and $15.97 per share for Series B, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization as set for the Company’s Certificate of Incorporation. As a result, as of December 31, 2023, each outstanding share of Series A and Series B is convertible into common stock on a 15.21 for 1 basis. The Convertible Preferred Stock automatically converts to common stock upon (1) an initial public offering totaling at least $31.94 per share, resulting in at least $75.0 million in proceeds, or (2) the date and time, or the occurrence of an event, specified by vote or written consent of (i) the holders of at least 55% of the voting power represented by the outstanding shares of Series A, voting together as a single class and (ii) the holders of at least 60% of the voting power represented by the outstanding shares of Series B, voting together as a single class. On January 26, 2024, the Convertible Preferred Stockholders waived the initial public offering per share parameter and as such, the Convertible Preferred Stock for both Series A and Series B were converted at the time of the initial public offering. Common Stock The holders of the common stock are entitled to one vote for each share of common stock held at all meetings of stockholders. Unless required by law, there shall be no cumulative voting. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, after the payment of all preferential amounts required to be paid to the holders of shares of Convertible Preferred Stock, the remaining funds and assets available for distribution to the stockholders of the Company will be distributed among the holders of shares of common stock, pro rata based on the number of shares of common stock held by each such holder. F-15 Table of Contents ARRIVENT BIOPHARMA, INC. NOTES TO THE FINANCIAL STATEMENTS Founders’ Shares In May 2021, the Company issued 1,314,914 shares of its common stock at a purchase price of $0.0015 per share, which are referred to as Founders’ Shares. The issuance price was equal to the estimated fair value of the common stock as the Founders’ Shares were issued shortly after the Company’s inception prior to raising any capital or acquiring any intellectual property. Prior to the second anniversary of the issuance date, the Company had the right to repurchase the Founders’ Shares at the original issuance price if the purchaser of the Founders’ Shares resigned employment or ceased to provide services to the Company. During the year ended December 31, 2023, the Company repurchased 7,387 Founders’ Shares from a holder upon the termination of their employment. The Company’s right to repurchase Founders’ Shares has lapsed. ​ ​ (9) Stock-based Compensation In June 2021, the Company adopted the 2021 Employee, Director and Consultant Equity Incentive Plan (the “Plan”), as amended, that authorized the Company to grant up to 803,564 shares of common stock. In 2022, the Company amended the Plan and increased the total number of shares authorized under the Plan to 2,748,818. As of December 31, 2023, there were 903,866 shares available to be granted. The Company’s stock options vest based on the terms in the awards agreements and generally vest over four years. The Company recorded stock-based compensation expense in the following expense categories in its accompanying statements of operations (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2023 2022 Research and development ​ $ 432 ​ $ 215 General and administrative ​ 463 ​ 209 ​ ​ $ 895 ​ $ 424 ​ The following is a summary of stock options activity under the Plan: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Weighted ​ average ​ ​ ​ ​ ​ ​ average ​ remaining ​ Aggregate ​ ​ ​ ​ exercise ​ contractual ​ Intrinsic Value ​ Options price term (years) (in thousands) Outstanding as of January 1, 2022 ​ 424,052 ​ $ 2.28 ​ ​ ​ ​ ​ Granted 699,450 ​ 2.28 ​ ​ ​ Exercised (6,574) ​ 2.28 ​ ​ ​ ​ Forfeited (38,133) ​ 2.28 ​ ​ ​ ​ Outstanding as of December 31, 2022 1,078,795 ​ 2.28 ​ ​ ​ ​ Granted 801,091 ​ 4.63 ​ ​ ​ Exercised (155,129) ​ 2.28 ​ ​ $ 595 Forfeited/expired ​ (41,601) ​ ​ 3.04 ​ ​ ​ ​ ​ Outstanding as of December 31, 2023 1,683,156 ​ ​ 3.38 8.59 ​ ​ 7,366 Exercisable as of December 31, 2023 366,135 ​ ​ 2.28 7.94 ​ ​ 2,005 Vested and expected to vest at December 31, 2023 1,683,156 ​ $ 3.38 8.59 ​ $ 7,366 ​ F-16 Table of Contents ARRIVENT BIOPHARMA, INC. NOTES TO THE FINANCIAL STATEMENTS The weighted-average grant-date fair value of options granted in 2023 and 2022 were $3.57 and $1.67 per share. The fair value was estimated using the Black-Scholes option-pricing model based on the following assumptions: ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ 2023 2022 Risk-free interest rate ​ 3.45% - 4.86% ​ ​ 1.70% - 4.01% Expected term ​ 5.5 - 6.1 years ​ 6 years Expected volatility ​ 89.3% - 92.5% ​ ​ 88.4% - 90.0% Expected dividend yield ​ — ​ — Estimated fair value of the Company's common stock per share ​ $ 2.71 - 4.86 $ 2.28 ​ Unrecognized compensation cost for awards not vested as of December 31, 2023 was $3.2 million and will be expensed over a weighted-average period of 2.7 years. ​ (10) Income Taxes The Company has incurred losses since inception and has not recorded current or deferred income taxes. A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the financial statements is as follows: ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, ​ ​ 2023 2022 ​ Tax at U.S. federal rate ​ 21.0 % 21.0 % State income taxes 5.5 0.1 ​ Other permanent differences (0.1) (0.1) ​ Research and development credit 3.2 3.4 ​ Rate change ​ 5.5 ​ — ​ Valuation allowance (35.1) (24.4) ​ Total provision — % — % ​ Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse. F-17 Table of Contents ARRIVENT BIOPHARMA, INC. NOTES TO THE FINANCIAL STATEMENTS Significant components of the Company’s deferred tax assets and liabilities for federal income taxes consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2023 2022 Deferred tax assets ​ ​ ​ ​ Net operating losses ​ $ 9,365 ​ $ 4,574 Research and development credit ​ 3,465 ​ 1,366 Intangible asset ​ 10,683 ​ 8,107 Capitalized research and development ​ 20,583 ​ 5,935 Other ​ 96 ​ 31 Gross deferred tax assets ​ 44,192 ​ 20,013 Valuation allowance ​ ​ (44,122) ​ ​ (19,984) Total deferred tax assets ​ 70 ​ 29 ​ ​ ​ ​ ​ ​ ​ Deferred tax liabilities ​ ​ Right of use asset ​ ​ (70) ​ (29) Total deferred tax liabilities ​ ​ (70) ​ ​ (29) Net deferred tax assets and liabilities ​ $ — ​ $ — ​ The Company records a valuation allowance against its deferred tax assets when it is more likely than not that realization will not occur. The realization of deferred tax assets depends upon the Company’s ability to generate future taxable income or other tax planning strategies available in the relevant taxing jurisdiction. In evaluating the realizability of its deferred tax assets, management must determine whether there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more-likely-than-not threshold for realizability. As a result, the Company recorded a valuation allowance against its deferred tax assets as of December 31, 2023 and 2022. The valuation allowance increased by $24.1 million and $9.0 million during the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023 and 2022, the Company had federal net operating loss (“NOL”) carryforwards of $38.9 million and $22.6 million, which will be carried forward indefinitely to offset future taxable income, subject to an eighty percent limitation of taxable income annually. In addition, state NOLs exist of $25.5 million and $0.7 million, which also carryforward indefinitely. The Company also had research and development tax credit carryforwards of $3.5 million and $1.4 million that will begin to expire in 2041. Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, (the “Code”) if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change NOL carryforwards and credits to offset its post-change income and taxes may be limited. In general, an “ownership change” occurs if there is a cumulative change in our ownership by one or more “5% shareholders” that exceeds 50 percentage points over a rolling three-year period. Similar rules apply under state tax laws. The Company has not determined if it has experienced Section 382/383 ownership changes in the past and if a portion of the Company’s NOL and tax credit carryforwards are subject to an annual limitation under Section 382/383. In addition, the Company may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of its control. As of December 31, 2023 and 2022, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company’s financial statements. The Company is generally subject to three-year statute of limitations for federal and state; therefore, 2021 through the current year remain open for examination. ​ F-18 Table of Contents ARRIVENT BIOPHARMA, INC. NOTES TO THE FINANCIAL STATEMENTS (11) Allist License Agreement In June 2021, the Company entered into a Global Technology Transfer and License Agreement with Allist (the “Allist Agreement”). Pursuant to the Allist Agreement, the Company was granted an exclusive license under certain intellectual property to develop, manufacture and commercialize certain licensed products in the field in the licensed territory. Upon execution of the Allist Agreement, the Company paid Allist a non-refundable cash payment of $40.0 million and issued 1,276,250 shares of its common stock. The upfront payment and fair value of the common stock issued have been recorded as acquired in-process research and development in the Company’s statements of operations since further development and regulatory approval of the licensed product candidates is necessary. Upon the achievement of certain clinical, regulatory and commercial milestones using the licensed technology, the Company is obligated to make future milestone payments to Allist. During the year ended December 31, 2023, the Company paid $5.0 million in clinical milestone payments to Allist. The Company is obligated to make future milestone payments of up to $105.0 million in clinical and regulatory milestones and $655.0 million in sales milestones. Furthermore royalties, ranging from high single digit percentages to low mid-teen percentage will be payable on net sales of licensed products in licensed territories. In connection with the Allist Agreement, in December 2021, the parties also entered into a Joint Clinical Collaboration Agreement (“Clinical Collaboration”) to define the framework under which the parties will cooperate and share costs related to global clinical studies to be conducted jointly by the Company and Allist. During the years ended December 31, 2023 and 2022, the Company incurred $2.0 million and $2.8 million, respectively, in cost reimbursements to Allist which have been recorded as research and development expense under the Clinical Collaboration Agreement. The Company also was entitled to cost reimbursement from Allist of $0.1 million and $0.8 million for the years ended December 31, 2023 and 2022, which has been recorded as a reduction of research and development expenses. The Company assessed the Clinical Collaboration in accordance with ASC 808, Collaborative Arrangements , and determined that the arrangement did not meet the definition of a collaborative arrangement under ASC 808 since, while the Company and Allist are active participants in the activities under the Clinical Collaboration, both parties are not exposed to significant risks and rewards dependent on the commercial success of the activities. ​ ​ ​ ​ ​ F-19 Table of Contents Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure None. ​